Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB104 Phase 1 Study in Colorectal Cancer
NCT05943041Phase 1Completed
- Sponsor
- GI Biome Co., Ltd.
- Start
- Apr 2023
- Primary completion
- Dec 2023
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label trial of GB104 in colorectal cancer (CRC) (3 arms), sponsored by GI Biome Co., Ltd. Primary endpoints: Incidence of Dose-Limiting Toxicity at 4 weeks and Incidence of Adverse Events at 8 weeks. Started Apr 2023; status: completed.
02
Drugs
GB104
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05943041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05943041.